At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AARD Aardvark Therapeutics
Trading 08-25 15:02:34 EDT
7.05
+0.17
+2.47%
High7.13Low6.49Vol94.01K
Open6.66D1 Closing6.88Amplitude9.30%
Mkt Cap152.96MTradable Cap78.74MTotal Shares21.70M
T/O647.64KT/O Rate0.84%Tradable Shares11.17M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Aardvark Therapeutics Lawsuit Alleges Investors Were Misled Before Sharp AARD Stock Drops
TIPRANKS  ·  08-21
Aardvark Therapeutics Lawsuit Alleges Investors Were Misled Before Sharp AARD Stock Drops
Aardvark Therapeutics Shareholders Approve Governance and Incentives
TIPRANKS  ·  08-18
Aardvark Therapeutics Shareholders Approve Governance and Incentives
Aardvark Therapeutics Held Annual Shareholder Meeting
Reuters  ·  08-18
Aardvark Therapeutics Held Annual Shareholder Meeting
Analysts Offer Insights on NA Companies: Nakamoto Inc (NAKA) and Aardvark Therapeutics, Inc. (AARD)
TIPRANKS  ·  08-15
Analysts Offer Insights on NA Companies: Nakamoto Inc (NAKA) and Aardvark Therapeutics, Inc. (AARD)
PDS Biotechnology Q2 Net Loss Widens Slightly as Operating Costs Fall
Reuters  ·  08-13
PDS Biotechnology Q2 Net Loss Widens Slightly as Operating Costs Fall
Grace Therapeutics Q1 Net Loss Widens on Impairment Charges
Reuters  ·  08-13
Grace Therapeutics Q1 Net Loss Widens on Impairment Charges
Stifel Nicolaus Keeps Their Hold Rating on Aardvark Therapeutics, Inc. (AARD)
TIPRANKS  ·  08-13
Stifel Nicolaus Keeps Their Hold Rating on Aardvark Therapeutics, Inc. (AARD)
Indaptus Q2 Net Loss Narrows as Costs Fall
Reuters  ·  08-13
Indaptus Q2 Net Loss Narrows as Costs Fall
AI Risk and Regulation: How Aardvark Therapeutics’ Use of Artificial Intelligence Could Expose It to Compliance, Cybersecurity, and Competitiveness Challenges
TIPRANKS  ·  08-13
AI Risk and Regulation: How Aardvark Therapeutics’ Use of Artificial Intelligence Could Expose It to Compliance, Cybersecurity, and Competitiveness Challenges
Atara Biotherapeutics Q2 Revenue Falls on Deferred Revenue Recognition
Reuters  ·  08-13
Atara Biotherapeutics Q2 Revenue Falls on Deferred Revenue Recognition
Aardvark Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-12
Aardvark Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Cypherpunk Technologies Swings to Q2 Profit on Zcash Gains
Reuters  ·  08-12
Cypherpunk Technologies Swings to Q2 Profit on Zcash Gains
Analysts Offer Insights on NA Companies: Smithfield Foods (SFD), Douglas AG (OtherDOUDF) and Aardvark Therapeutics, Inc. (AARD)
TIPRANKS  ·  08-12
Analysts Offer Insights on NA Companies: Smithfield Foods (SFD), Douglas AG (OtherDOUDF) and Aardvark Therapeutics, Inc. (AARD)
Aardvark Therapeutics Q2 Operating Expenses Fall on Paused ARD-101 Clinical Trials and Workforce Reduction
Reuters  ·  08-12
Aardvark Therapeutics Q2 Operating Expenses Fall on Paused ARD-101 Clinical Trials and Workforce Reduction
Aardvark Therapeutics Inc Q2 Net Income USD -14.387 Million VS. Ibes Estimate USD -20.6 Million
THOMSON REUTERS  ·  08-12
Aardvark Therapeutics Inc Q2 Net Income USD -14.387 Million VS. Ibes Estimate USD -20.6 Million
Aardvark Therapeutics Q2 EPS $-0.66
THOMSON REUTERS  ·  08-12
Aardvark Therapeutics Q2 EPS $-0.66
Aardvark Therapeutics Inc Q2 Operating Expenses USD 15.084 Million
THOMSON REUTERS  ·  08-12
Aardvark Therapeutics Inc Q2 Operating Expenses USD 15.084 Million
Aardvark Therapeutics Inc Q2 Income from Operations USD -15.084 Million
THOMSON REUTERS  ·  08-12
Aardvark Therapeutics Inc Q2 Income from Operations USD -15.084 Million
Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Dow Jones  ·  08-12
Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Aardvark Therapeutics, Inc. Expected to Post a Loss of 87 Cents a Share - Earnings Preview
Reuters  ·  08-07
Aardvark Therapeutics, Inc. Expected to Post a Loss of 87 Cents a Share - Earnings Preview

Introduction

Company Name.
Aardvark Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--